TET1 and acute lymphoblastic leukemia: Bamezai et al. outlined that PARP could induce TET1 expression, thus TET1 could be pharmacologically targeted via application of PARP inhibitor Olaparib, which showed great therapeutic potential in T-ALL treatment (Bamezai et al., 2021).